Cefepime-induced neurotoxicity

Central Nervous System Agents in Medicinal Chemistry

Volumn 8, Issue 4, 2008, Pages 229-233

  Bragatti, José Augusto ^a,b  

^a Hospital de Clínicas de Porto Alegre ^*  (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID CARRIER; ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA LACTAMASE; BILIRUBIN; CALCIUM; CEFEPIME; CEPHALOSPORIN; CREATININE; PENICILLIN G; PHOSPHORUS; POTASSIUM; TIAGABINE; UREA;

AGITATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIMICROBIAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATAXIA; BACTERIAL CELL WALL; BACTERIAL OUTER MEMBRANE; BILIRUBIN BLOOD LEVEL; BRAIN LATERAL VENTRICLE; CALCIUM BLOOD LEVEL; CEFEPIME INDUCED ENCEPHALOPATHY; CELL SYNCHRONIZATION; CHLORIDE CURRENT; COLITIS; COMA; CONFUSION; CONVULSION; COOMBS TEST; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; ELECTROENCEPHALOGRAM; EOSINOPHILIA; EPILEPSY; EPILEPTIC STATE; FEVER; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HEMATOCRIT; HEMOLYSIS; HUMAN; HYPOPHOSPHATEMIA; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE PHLEBITIS; INJECTION SITE RASH; KIDNEY CLEARANCE; LEUKOCYTE; MYOCLONUS SEIZURE; NAUSEA; NERVE CELL CULTURE; NERVE CELL NETWORK; NERVOUSNESS; NEUROTOXICITY; NEUTROPHIL; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PRESYNAPTIC MEMBRANE; PROTEIN HYDROLYSIS; PROTHROMBIN TIME; PRURITUS; REVIEW; SEIZURE; SIDE EFFECT; SOMNOLENCE; THROMBOCYTE; THRUSH; TREMOR; UREA BLOOD LEVEL; URTICARIA; VAGINITIS; VOMITING; XENOPUS LAEVIS;

EID: 57749083165     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152408786848139     Document Type: Review

References (55)

1. Wynd, M.A.; Paladino, J.A. Ann. Pharmacother., 1996, 30, 1414.
2. Neu, H.C. Am. J. Med., 1996, 68.
3. Marino, P.L. In The I.C.U. Book; Paul L. Marino, Ed.; Lippincott Williams & Wilkins: Baltimore, 1998; pp. 562-578.
4. Plum, F.; Posner, J.B. The Diagnosis of Stupor and Coma, F.A. Davis: Philadelphia, 1980.
5. Gerace, R.V. In Coma and Impaired Consciousness: a Clinical Perspective; G. Bryan Young; Allan H. Ropper; Charles F. Bolton, Eds.; Mc Graw Hill: New York, 1998. pp. 457-469.
6. Chetaille, E.; Hary, L.; de Cagny, B.; Gras-Champel, V.; Decocq, G.; Andrejak, M. Therapie, 1997, 52, 167.
7. Wong, K.M.; Chan, W.K.; Chan, Y.H.; Li, C.S. Nephrol. Dial. Transplant., 1999, 14, 2265.
8. Dixit, S.; Kurle, P.; Buyan-Dent, L.; Sheth, R.D. Neurology, 2000, 54, 2153.
9. Fishbain, J.T; Monahan, T.P.; Canonico, M.M. Neurology, 2000, 55, 1756.
10. Jallon, P.; Frankhause, R.L.; Du Pasquier, R.; Coeytaux, A.; Picard, F.; Hefft, S.; Assal, F. Neurophysiol. Clin., 2000, 30, 383.
11. Saurina, A.; Vera, M.; Pou, M. Nefrologia, 2000, 20, 554.
12. Barbey, F.; Bugnon, D.; Wauter, J.P. Ann. Intern. Med., 2001, 135, 1011.
13. Martínez-Rodríguez, J.E.; Barriga, F.J.; Santamaría, J.; Iranzo, A.; Pareja, J.A.; Revilla, M.; dela Rosa, C.R. Am. J. Med., 2001, 111, 115.
14. Chandrasekhar, J.; Keller, S.; Scanlon, P. Chest, 2002, 122, 256.
15. Chatellier, D.; Jourdain, M.; Mangalaboyi, J.; Ader, F.; Chopin, C.; Derambure, P.; Fourrier, F. Int. Care Med., 2002, 28, 214.
16. Chow, K.M.; Szeto, C.C.; Hui, A.C.-F.; Wong, T.Y.-H; Kam-Tao, P. Pharmacotherapy, 2003, 23, 369.
17. Ferrara, N.; Abete, P.; Giordano, M. Clin. Nephrol., 2003, 59, 388.
18. Abanades, S.; Nolla, J.; Rodríguez-Campello, A.; Pedro, C.; Valls, A.; Farré, M. Ann. Pharmacother., 2004, 38, 606.
19. Alpay, H.; Altun, O.; Kiyikli, N. Pediatr. Nephrol., 2004, 19, 445.
20. Dakdouki, G.K.; Al-Awar, G.N. Int. J. Infect. Dis., 2004, 8, 59.
21. Primavera, A., Cocito, L.; Audenino, D. Neuropsychobiology, 2004, 49, 218.
22. Sanchez-Bailen, M.J.; Ciruelos, N.; Garcia-Marron, R.; Angles Coll, R. Rev. Clin. Esp., 2004, 204, 501.
23. Bragatti, J.A.; Rossatto, R.; Ziomkowski, S.; Kliemann, F.A.D. Arq. Neuropsiquiatr., 2005, 63, 87.
24. Camparelli, F.J.; Diaz, M.F.; Hlavnika, A.; Wainsztein, N.A.; Leiguarda, R.; Del Castillo, M.E. Neurology, 2005, 65, 1840.
25. Fernández-Torre, J.L.; Martínez-Martínez, M.; González-Rato, J.; Maestro, I.; Alonso, I.; Rodrigo, E.; Horcajada, J.P. Epilepsia, 2005, 46, 1550.
26. Lam, S.; Gomolim, I.H. Pharmacotherapy, 2006, 26, 1169.
27. Maganti, R.; Jolin, D.; Rishi, D.; Biswas, A. Epilepsy Behav., 2006, 8, 312.
28. De Silva, D.A.; Pan, A.B.; Lim, S.H. Ann. Acad. Med. Singapore, 2007, 36, 450.
29. Yahav, D.; Paul, M.; Fraser, A.; Sarid, N.; Leibovici, L. Lancet Infect. Dis., 2007, 7, 338.
30. U.S. Food and Drug Administration. Maxipime. (Cefepime hydrochloride) for injection. NDA 50-679/S-021. http://www.fda.gov/medwatch/SAFETY/2003/ 03MAR_PI/Maxipime_PI.pdf (accessed 23/11/2007).
31. Barradell, L.B.; Bryson, H.M. Drugs, 1994, 47, 471.
32. Kessler, R.E.; Fung-Tome, J. Am. J. Med., 1993, 95, 10.
33. Conrad, D.A.; Scribner, R.K.; Weber, A.H.; Marks, M.I. Antimicrob. Agents Chemother., 1985, 28, 58.
34. Masuyoshi, S.; Hiraoka, M.; Inoue, M.; Tomatsu, K.; Hirano, M.; Mitsuhashi, S. Drug Exp. Clin. Res., 1989, 15, 1.
35. Barbhaiya, R.H.; Forgue, S.T.; Gleason, C.R.; Knupp, C.A.; Pittman, K.A.; Weidler, D.J.; Movahhed, H.; Tenney Martin, R.R. Antimicrob. Agents Chemother., 1992, 36, 552.
36. Barbhaiya, R.H.; Knupp, C.A.; Forgue, S.T.; Matzke, G.R.; Guay, D.R.; Pittman, K.A. Clin. Pharmacol. Ther., 1990, 48, 268.
37. Shimada, J.; Kanemitsu, K.; Shoji, Y.; Nakashio, S.; Yanagawa, A. Drugs Exp. Clin. Res., 1992, 18, 377.
38. Chatrian, G.E.; Tunella, G.S. In Current Practice of Clinical Electroencephalography; John S. Ebersole; Thimothy A. Pedley, Eds.; Lippincott Williams & Wilkins: Philadelphia, 2003, pp. 403-462.
39. Kaplan, P.W. J. Clin. Neurophysiol., 2006, 23, 221.
40. Kaplan, P.W. J. Clin. Neurophysiol., 1999, 16, 341.
41. Drislane, F.W. Epilepsy Behav., 2000, 1, 301.
42. Chow, K.M.; Hui, A.C.; Szeto, C.C. Eur. J. Clin. Microbiol. Infect. Dis., 2005, 24, 649.
43. Sugimoto, M.; Uchida, I.; Máximo, T.; Yamazaki, S.; Hatano, K.; Ikeda, F.; Mochizuki, Y.; Terai, T.; Matsuoka, N. Neuropharmacology, 2003, 45, 304.
44. Study, R.E.; Barker, J.L. Proc. Natl. Acad. Sci. USA, 1981, 78, 7180.
45. Barker, J.L.; McBurney, R.N.; Mathers, D..A. Br. J. Pharmacol., 1983, 80, 619.
46. Akaike, N.; Hattori, K.; Oomura, Y.; Carpenter, D.O. Experimentia, 1985, 41, 70.
47. Barnard, E.A.; Skolnick, P.; Olsen, R.W.; Mohler, H.; Sieghart, W.; Biggio, G.; Braestrup, C.; Bateson, A.N.; Langer, S.Z. Pharmacol. Rev., 1998, 50, 291.
48. Hwa, G.G.C.; Avoli, M. Neurosci. Lett., 1989, 98, 189.
49. Raiteri, M. Pharmacol. Rev., 2006, 58, 162.
50. Avoli, M.; Louvel, J.; Pumain, R.; Köhling, R. Prog. Neurobiol., 2005, 77, 166.
51. Richerson, G.B.; Wu, Y. J. Neurophysiol., 2003, 90, 1363.
52. Richerson, G.B.; Wu, Y. Adv. Exp. Med. Biol., 2004, 548, 76.
53. Sills, G.J. Epileptic Disord., 2003, 5, 51.
54. Aldenkamp, A.P.; De Krom, M.; Reijs, R. Epilepsia, 2003, 44 , 21.
55. Wikipedia. http://en.wikipedia.org/wiki/Paracelsus#_note-2(accessed 25/11/2007).